Dott.ssa Mattavelli Ilaria
Doctor
Contacts
- Mail: ilaria.mattavelli@istitutotumori.mi.it
- Tel: 02.23903658
Specialty / Department
- Surgery
Ilaria Mattavelli is a general surgeon working at the Fondazione IRCCS Istituto Nazionale dei Tumori, in Milan.
She received her medical degree from the University of Milan in 2008, and is board certified as a general surgeon physician in 2015. and she’s working as Melanoma Surgeon at Melanoma Surgical Melanoma Unit of Istituto Nazionale Tumori since 2015.
Her main research interests are melanoma and non-melanoma skin cancers from 2011 when she attended Istituto Nazionale Tumori as a resident in General Surgery.
In 2016 she attended Melanoma Institute Australia in Sydney as Honourary Observer for 5 months.
Dr. Mattavelli is a member of the Italian Melanoma Intergroup (IMI) and EORTC and takes active part in the development and management of clinical and research activities in the field of melanoma. She has actively taken part on clinical trials as “COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBination with trametinib (GSK1120212) versus two placebos in the Adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection” and “A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients”. She’s taking part to “Immune system activation by electrochemotherapy: hypothesis validating within a prospective study” .
She actively takes part to MDT meetings regarding melanoma and non-melanoma slin cancers.
Dr. Mattavelli has a surgical activity and clinical research activity with production of papers on melanoma and non melanoma skin cancers surgery.
She took part to several national and international congresses as speaker.
Mattavelli I, Patuzzo R, Galeone C, Pelucchi C, Gallino G, Leva A, Valeri B, Santinami M, Maurichi A.
Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study. Melanoma Res. 2023 May 8.
Patuzzo R, Mattavelli I, Gallino G, Galeone C, Valeri B, Mocellin S, Del Fiore P, Ribero S, Mandalà M, Tauceri F, Lombardo M, Maurichi A; Italian Melanoma Intergroup.The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
Cancer. 2023 May 10
Maurichi A, Barretta F, Patuzzo R, Sala L, Miceli R, Gallino G, Mattavelli I, Leva A, Simonotti N, Taglione B, Cossa M, Belotti A, Valeri B, Cortinovis U, Santinami M.
Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures. JAMA Dermatol. 2023 Apr 12:e230620
Maurichi A, Barretta F, Patuzzo R, Miceli R, Gallino G, Mattavelli I, Leva A, Harwood C, Bergamaschi D, Borg TM, Shimonovitz-Moore M, Spadola G, Tolomio E, Barbieri C, Queirolo P, Manganoni AM, Pellacani G, Espeli V, Mangas C, Leoni-Parvex S, Cossa M, Belotti A, Valeri B, Cortinovis U, Santinami M. Similar local recurrence and survival in patients with T1 radial growth phase melanoma on head and neck treated with 5 or 10 mm margins: A retrospective study. J Eur Acad Dermatol Venereol. 2023 Mar 16
Maurichi A, Barretta F, Patuzzo R, Miceli R, Gallino G, Mattavelli I, Barbieri C, Leva A, Angi M, Lanza FB, Spadola G, Cossa M, Nesa F, Cortinovis U, Sala L, Di Guardo L, Cimminiello C, Del Vecchio M, Valeri B, Santinami M. Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension J Natl Compr Canc Netw. 2021 Jul 26;19(10):1165-1173.
Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
Oncologist. 2021 Dec;26(12):1079-1084
Mattavelli I, Maurichi A, Galeone C, Gallino G, Barbieri C, Leva A, Tolomio E, Valeri B, Cossa M, Patuzzo R, Santinami M. The role of sentinel lymph node status performed in melanoma patients with local recurrence or in transit metastasis.
Eur J Surg Oncol. 2021 May;47(5):1152-1156. doi: 10.1016/j.ejso.2020.10.028. Epub 2020 Nov 1. PMID: 33218700
Gallino G, Maurichi A, Patuzzo R, Mattavelli I, Barbieri C, Leva A, Valeri B, Cossa M, Galeone C, Pelucchi C, Santinami M. Surgical treatment of melanoma metastases to the small bowel: A single cancer referral center real-life experience.
Eur J Surg Oncol. 2021 Feb;47(2):409-415. doi: 10.1016/j.ejso.2020.08.025. Epub 2020 Aug 29. PMID: 32917431
Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M.
Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.
J Clin Oncol. 2020 May 10;38(14):1591-1601. doi: 10.1200/JCO.19.01902. Epub 2020 Mar 13
Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. Reply to E. Hindié.
J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23.
Maurichi A, Miceli R, Patuzzo R, Barretta F, Gallino G, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Tolomio E, Sant M, Castelli G, Zichichi L, Pellacani G, Stanganelli I, Simonacci M, Manganoni A, Del Forno C, Caresana G, Harwood C, Bergamaschi D, Lasithiotakis K, Bennett D, Espeli V, Mangas C, Leoni Parvex S, Valeri B, Cossa M, Barisella M, Pellegrinelli A, Miranda C, Anichini A, Mortarini R, Zoras O, Santinami M. Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors.
J Natl Compr Canc Netw. 2020 Oct 1;18(10):1327-1336. doi: 10.6004/jnccn.2020.7582. Print 2020 Oct. PMID: 33022642
Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G, Mattavelli I, Vergani B, Lalli L, Tamborini E, Valeri B, Gargiuli C, Shahaj E, Ferrarini M, Ferrero E, Gomez Lira M, Huber V, Del Vecchio M, Sensi M, Leone BE, Santinami M, Rivoltini L, Rodolfo M, Vallacchi V. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.Cell Commun Signal. 2020 Sep 23;18(1):156
Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Target Oncol. 2018 Oct;13(5):567-582.
Mattavelli I, Patuzzo R, Torri V, Gallino G, Maurichi A, Lamera M, Valeri B, Bolzonaro E, Barbieri C, Tolomio E, Moglia D, Nespoli AM, Galeone C, Saw R, Santinami M.
Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy.
Eur J Surg Oncol. 2017 Aug;43(8):1536-1541.
Sandini M, Mattavelli I, Nespoli L, Uggeri F, Gianotti L.
Systematic review and meta-analysis of sutures coated with triclosan for the prevention of surgical site infection after elective colorectal surgery according to the PRISMA statement. Medicine (Baltimore). 2016 Aug;95(35)
Mattavelli I, Rebora P, Doglietto G, Dionigi P, Dominioni L, Luperto M, La Porta A, Garancini M, Nespoli L, Alfieri S, Menghi R, Dominioni T, Cobianchi L, Rotolo N, Soldini G, Valsecchi MG, Chiarelli M, Nespoli A, Gianotti L. Multi-Center Randomized Controlled Trial on the Effect of Triclosan-Coated Sutures on Surgical Site Infection after Colorectal Surgery. Surgical Infections. June 2015, 16(3): 226-235.
Patuzzo R, Maurichi A, Camerini T, Gallino G, Ruggeri R, Baffa G, Mattavelli I, Tinti MC, Crippa F, Moglia D, Tolomio E, Maccauro M, Santinami M. Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. J Surg Res. 2014 Apr;187(2):518-24. Epub 2013 Oct 23.
Ruggeri R, Camerini T, Patuzzo R, Maurichi A, Pirovano R., Mattavelli I, Crippa F. Tolomio E., Moglia D, Di Florio A, Santinami M, The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs, Int J Surg Case Report 2013;4(1):40-3. 2012 Sep 27
Garancini M, Gianotti L, Mattavelli I, Romano F, Degrate L, Caprotti R, Nespoli A, Uggeri F. Bipolar Vessel Sealing System vs Clamp crushing technique for liver parenchima transection. Hepatogastroenterology 2011 Jan-Feb;58(105):127-32.
- A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients. (PH-L19IL2TNF-0215), find the attachment
- Immune system activation by elettrochemotherapy: Hypothesis validating within a prospetive study . (Immune-ECT), find the attachment
- Risk assessment of local recurrence in patient with melanoma in situ not undergone wide local excision after diagnostic excision. (MEL_INSITU), find the attachment
- Outcome evaluation of patients with melanoma and positive sentinel node after MSLT-II and DeCOG trials and the advent of adjuvant therapies. (Melanoma_SN+), find the attachment
Oncologic General Surgery 4 - Melanoma and Eye Tumors
Last update: 04/11/2025